MA55757A - Procédé de préparation de formulations peptidiques stables - Google Patents

Procédé de préparation de formulations peptidiques stables

Info

Publication number
MA55757A
MA55757A MA055757A MA55757A MA55757A MA 55757 A MA55757 A MA 55757A MA 055757 A MA055757 A MA 055757A MA 55757 A MA55757 A MA 55757A MA 55757 A MA55757 A MA 55757A
Authority
MA
Morocco
Prior art keywords
preparing stable
peptide formulations
stable peptide
formulations
preparing
Prior art date
Application number
MA055757A
Other languages
English (en)
Inventor
Gregory Nelson Brown
Scoik Kurt Gard Van
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA55757A publication Critical patent/MA55757A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MA055757A 2019-04-26 2020-04-20 Procédé de préparation de formulations peptidiques stables MA55757A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962839246P 2019-04-26 2019-04-26

Publications (1)

Publication Number Publication Date
MA55757A true MA55757A (fr) 2022-03-02

Family

ID=70554273

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055757A MA55757A (fr) 2019-04-26 2020-04-20 Procédé de préparation de formulations peptidiques stables

Country Status (22)

Country Link
US (1) US12508229B2 (fr)
EP (1) EP3958838B1 (fr)
JP (2) JP7245926B2 (fr)
KR (1) KR102832458B1 (fr)
CN (1) CN113727700B (fr)
AR (1) AR118690A1 (fr)
AU (1) AU2020261941B2 (fr)
BR (1) BR112021018325A2 (fr)
CA (1) CA3134757A1 (fr)
CL (1) CL2021002690A1 (fr)
CO (1) CO2021014034A2 (fr)
EA (1) EA202192475A1 (fr)
EC (1) ECSP21079422A (fr)
IL (1) IL286426B2 (fr)
MA (1) MA55757A (fr)
MX (1) MX2021012852A (fr)
PE (1) PE20212368A1 (fr)
PH (1) PH12021552708A1 (fr)
SG (1) SG11202110413YA (fr)
TW (1) TWI771669B (fr)
UA (1) UA129294C2 (fr)
WO (1) WO2020219391A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116718762B (zh) * 2023-06-09 2025-01-24 上海品峰医疗科技有限公司 一种多肽类样本稳定剂

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179079A (en) 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
DK49791D0 (da) 1991-03-20 1991-03-20 Novo Nordisk As Nasalt pulverpraeparat
US7118675B2 (en) 2002-02-04 2006-10-10 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
DK2158214T3 (da) 2007-06-15 2011-12-05 Zealand Pharma As Glukagonanaloger
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
WO2010070252A1 (fr) 2008-12-15 2010-06-24 Zealand Pharma A/S Analogues du glucagon
JP5635529B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
NZ593813A (en) 2008-12-15 2013-02-22 Zealand Pharma As Glucagon analogues
ME02220B (me) 2009-07-13 2016-02-20 Zealand Pharma As Analozi acilovanog glukagona
US9610329B2 (en) 2009-10-22 2017-04-04 Albireo Pharma, Inc. Stabilized glucagon solutions
WO2011117417A1 (fr) 2010-03-26 2011-09-29 Novo Nordisk A/S Nouveaux analogues de glucagon
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
EP2585482B1 (fr) 2010-06-24 2019-03-27 Zealand Pharma A/S Analogues de glucagon
BR112013032717A2 (pt) 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp coagonistas do receptor de glucagon/glp-1
SG11201403377QA (en) 2011-12-23 2014-07-30 Zealand Pharma As Glucagon analogues
FI124134B (en) 2012-07-02 2014-03-31 One Way Sport Oy Binding between a ski and a ski boot
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
US9018162B2 (en) * 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
MA52253A (fr) 2015-02-17 2021-02-17 Lilly Co Eli Formulation de poudre nasale pour le traitement de l'hypoglycémie
BR112018001900A2 (pt) * 2015-07-28 2018-09-18 Otonomy, Inc. composições agonistas de trkb ou trkc e métodos para o tratamento de condições óticas
JP7001584B2 (ja) * 2015-09-04 2022-01-19 ラティチュード ファーマシューティカルズ インコーポレイテッド 安定化されたグルカゴン溶液

Also Published As

Publication number Publication date
EP3958838A1 (fr) 2022-03-02
US12508229B2 (en) 2025-12-30
JP2023075249A (ja) 2023-05-30
IL286426B2 (en) 2025-06-01
TWI771669B (zh) 2022-07-21
MX2021012852A (es) 2021-12-10
JP2022529614A (ja) 2022-06-23
EP3958838C0 (fr) 2025-09-10
JP7245926B2 (ja) 2023-03-24
UA129294C2 (uk) 2025-03-12
CO2021014034A2 (es) 2021-10-29
JP7615426B2 (ja) 2025-01-17
EA202192475A1 (ru) 2022-01-28
TW202108599A (zh) 2021-03-01
CN113727700A (zh) 2021-11-30
KR102832458B1 (ko) 2025-07-10
PH12021552708A1 (en) 2022-03-21
AR118690A1 (es) 2021-10-27
NZ781188A (en) 2024-07-26
ECSP21079422A (es) 2021-11-30
US20220192988A1 (en) 2022-06-23
AU2020261941B2 (en) 2023-04-06
IL286426A (en) 2021-10-31
IL286426B1 (en) 2025-02-01
CA3134757A1 (fr) 2020-10-29
CL2021002690A1 (es) 2022-07-08
EP3958838B1 (fr) 2025-09-10
KR20210143253A (ko) 2021-11-26
PE20212368A1 (es) 2021-12-21
AU2020261941A1 (en) 2021-10-14
BR112021018325A2 (pt) 2021-11-23
WO2020219391A1 (fr) 2020-10-29
SG11202110413YA (en) 2021-10-28
CN113727700B (zh) 2024-09-17

Similar Documents

Publication Publication Date Title
MA53544A (fr) Procédé de préparation de compositions de vaccin
MA52204A (fr) Procédés de préparation de compositions protéiques stables
SG11202109277WA (en) Stable protein formulations
EP3939962A4 (fr) Procédé de préparation d'un dérivé d'acide aminé aromatique
IL288153A (en) Stabilized formulations containing anti-angptl3 antibodies
EP3904323A4 (fr) Procédé de préparation de 1,4-cyclohexanediméthanol
EP3504318C0 (fr) Procédé d'amélioration de l'activité de la méthyltransférase
EP4015519A4 (fr) Procédé de préparation d'asénapine
IL285674A (en) Pharmaceutical formulations
MA54396A (fr) Procédé de préparation de n-phénylpyrazole-1-carboxamides
IL289637A (en) Plant holder for hydroponic system
EP3766869A4 (fr) Procédé simple de préparation d'avibactam
EP3965724A4 (fr) Formulations et procédés de préparation de compositions cosmétiques stables
EP3858833A4 (fr) Dérivé d'aminonordécane, son procédé de préparation et son utilisation
EP3852617A4 (fr) Procédés de réversion d'activité de ticagrélor
EP3978033A4 (fr) Produit radiopharmaceutique polypeptidique rk ciblant her2, et procédé de préparation associé
DK3923914T3 (da) Afabicin-formulering, fremgangsmåde til fremstilling deraf
EP3325496A4 (fr) Procédé de préparation d'un conjugué polypeptidique physiologiquement actif
EP3645548A4 (fr) Procédés de préparation d'acides biliaires
EP4013441A4 (fr) Formulations de larazotide
MA53346A (fr) Composition de vaccin muqueux pour la mastite bovine
PL3746441T3 (pl) Związek farmaceutyczny, jego sole, jego preparaty oraz sposoby ich wytwarzania i zastosowania
DK4027973T3 (da) Formuleringer til lægemiddeladministration
MA55757A (fr) Procédé de préparation de formulations peptidiques stables
EP3835300A4 (fr) Dérivé de 1,7-naphtyridine, son procédé de préparation et d'utilisation